Related Experiment Video
Updated: Jun 11, 2025
10:55
Rescue of Recombinant Newcastle Disease Virus from cDNA
Published on: October 11, 2013
19.3K
AP3B1 Has Type I Interferon-Independent Antiviral Function against SARS-CoV-2
Gayatri Subramanian1, Adam Hage2, Friederike Feldmann3
1Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Viruses
|September 28, 2024
Summary
The adaptor protein complex 3 (AP-3) subunit B1 (AP3B1) interacts with SARS-CoV-2, but surprisingly suppresses virus replication, acting as an antiviral factor. This suggests targeting AP3B1 could be a therapeutic strategy against SARS-CoV-2 infection.
Area of Science:
- Virology
- Cell Biology
- Immunology
Background:
- Proteomic studies identified host-virus interactions in SARS-CoV-2 infection.
- The functional consequences of these interactions for viral replication remain largely unexplored.
- A common interaction identified is between host AP3B1 and the SARS-CoV-2 E protein.
Purpose of the Study:
- To investigate the role of host adaptor protein complex 3 (AP-3) subunit B1 (AP3B1) in the SARS-CoV-2 replication cycle.
- To determine if the interaction between AP3B1 and the SARS-CoV-2 E protein influences viral replication.
- To assess the potential of AP3B1 as a therapeutic target.
Main Methods:
- Confirmation of AP3B1 and SARS-CoV-2 E protein interaction using immunoprecipitation (IP) and immunofluorescence assays (IFA) in infected cells.
- Experimental manipulation of AP3B1 levels through overexpression and siRNA-mediated depletion.
- Assessment of infectious virus release following AP3B1 modulation.
Main Results:
- Overexpression of AP3B1 was found to suppress SARS-CoV-2 replication.
- Depletion of AP3B1 using siRNA led to an increase in infectious virus release.
- These findings indicate an antiviral role for AP3B1 in SARS-CoV-2 infection.
Conclusions:
- AP3B1 acts as an intrinsic barrier to SARS-CoV-2 replication, potentially through its interaction with the viral E protein.
- The study highlights the importance of lysosomal-related organelle (LRO) trafficking in SARS-CoV-2 target cells and viral pathogenesis.
- Further research into LRO trafficking could reveal new therapeutic avenues for COVID-19.
More Related Videos
Related Concept Videos
01:29Immune Response Against Viral Pathogens
760
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
760
02:28Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
01:23RNA Interference
26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K